Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK
- PMID: 34223066
- PMCID: PMC8210269
- DOI: 10.1093/jacamr/dlaa114
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK
Abstract
These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, taking into account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Figures
References
-
- Gould FK, Brindle R, Chadwick PR et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849–61. - PubMed
-
- Cochrane. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). 2019. www.training.cochrane.org/handbook.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources